share_log

HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Lowers Price Target to $34

HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Lowers Price Target to $34

HC Wainwright & Co.重申買入庫裏南腫瘤學,將目標股價下調至34美元
Benzinga ·  2023/08/11 13:10

HC Wainwright & Co. analyst Edward White reiterates Cullinan Oncology (NASDAQ:CGEM) with a Buy and lowers the price target from $49 to $34.

HC Wainwright & Co. 分析師愛德華·懷特重申了庫裏南腫瘤學(納斯達克股票代碼:CGEM)的買入,並將目標股價從49美元下調至34美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論